A Form 4 filed with the SEC on September 1, 2026, discloses that Mark Alvino, a director of Abeona Therapeutics Inc. (NASDAQ:ABEO), sold 15,000 shares of common stock on September 1, 2026.

Key Highlights

  • Reporting person: Mark Alvino, identified as a Director of Abeona Therapeutics Inc.
  • Transaction: 15,000 shares of common stock disposed of (transaction code S) on September 1, 2026.
  • Weighted average price: $5.8644 per share, with individual sale prices ranging from $5.80 to $5.9250 inclusive.
  • Remaining ownership: 62,065 shares of common stock held directly following the transaction.
  • Multiple transactions: Shares were sold across multiple transactions within the stated price range on the same date.

Director Mark Alvino's Share Sale at Abeona Therapeutics

According to the Form 4 filing, Mark Alvino, a director of Abeona Therapeutics Inc., disposed of 15,000 shares of the company's common stock on September 1, 2026. The transaction is reported under code "S," indicating an open-market sale. The filing lists the price as a weighted average of $5.8644 per share.

The filing notes in its explanation of responses that the reported price "is a weighted average price" and that "these shares were sold in multiple transactions at prices ranging from $5.80 to $5.9250 inclusive." Alvino undertakes, per the filing, to provide full information regarding the number of shares sold at each separate price upon request by the issuer, any security holder, or SEC staff.

Following the reported transaction, Alvino beneficially owns 62,065 shares of Abeona Therapeutics common stock directly. No derivative securities transactions were reported in Table II of the filing. The form was signed by Mark Alvino and dated September 1, 2026.

What Was Disclosed

The filing reports that Abeona Therapeutics director Mark Alvino sold 15,000 shares of common stock on September 1, 2026, at a weighted average price of $5.8644, leaving him with 62,065 shares held directly.